Agios Pharmaceuticals, Inc.
AGIO
$26.70
$1.395.49%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 51.06% | 21.15% | 28.35% | 46.00% | 64.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.06% | 21.15% | 28.35% | 46.00% | 64.80% |
| Cost of Revenue | 7.68% | -11.20% | 12.70% | 2.05% | 10.41% |
| Gross Profit | -3.34% | 14.39% | -11.04% | 1.91% | -6.88% |
| SG&A Expenses | 46.43% | 49.24% | 16.86% | 9.33% | 7.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.75% | 3.21% | 13.96% | 4.20% | 9.56% |
| Operating Income | -17.65% | -1.90% | -12.93% | -1.61% | -7.16% |
| Income Before Tax | -9.86% | 1,196.14% | -14.69% | -0.66% | -362.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.61% | 1,137.97% | -14.69% | -0.66% | -362.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.61% | 1,137.97% | -14.69% | -0.66% | -362.66% |
| EBIT | -17.65% | -1.90% | -12.93% | -1.61% | -7.16% |
| EBITDA | -17.92% | -2.21% | -13.42% | -2.14% | -7.72% |
| EPS Basic | 1.46% | 1,117.28% | -12.27% | 1.34% | -358.09% |
| Normalized Basic EPS | -7.59% | 5.46% | -12.27% | 1.33% | -6.25% |
| EPS Diluted | 1.67% | 1,089.02% | -12.27% | 1.34% | -358.63% |
| Normalized Diluted EPS | -7.59% | 7.87% | -12.27% | 1.33% | -6.25% |
| Average Basic Shares Outstanding | 2.10% | 2.04% | 2.15% | 2.02% | 1.77% |
| Average Diluted Shares Outstanding | 2.10% | 4.71% | 2.15% | 2.02% | 1.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
